"Wouldn't you think it would bd worth alot more than Amarin,... given the 2 other indications being tested and the potential of 2000 more,...plus with the RVX epigenetics technology being 10 years ahead of anyone else."

Vascepa was already FDA approved for triglyceride lowering before REDUCE-IT and Amarin has still yet to be approved by FDA to market for MACE reduction. Resverlogix does not have an FDA approved product yet. From this perspective, Amarin had a kind of head start relative to Resverlogix. Amarin sales of Vascepa have already increased prior to regulatory agency approval of marketing for MACE reduction. Even if BETonMACE succeeds, EMA/FDA applications will still need to be filed and approved before apabetalone can be marketed/sold for anything.

Vascepa is an omega-3 drug. Omega-3's have been implicated in A LOT of conditions including but not limited to cognition, metabolic diseases and inflammation. So there is A LOT of potential for additional indications for Vascepa. Amarin has other trials ongoing to pursue some of these. A disadvantage for Amarin is that competing omega-3 products currently in clinical trials and/or FDA approved could take away market share sooner than competitors in the BET inhibitor space. For example, Astrazeneca's EPANOVA STRENGTH trial CVOT reads out this year. So imminent competition is more of a concern for Amarin than it is for Resverlogix. Epigenetic drugs, including BET inhibitors, are largely limited to the oncology space right now, which carves out quite a unique niche for Resverlogix/Apabetalone for the near future.

BearDownAZ

P.S. Growacet, I posted a pretty lengthy comment to your excellent Seeking Alpha article.